1 week Ago By Defense World Staff
Prudential Financial Inc. bought a new stake in shares of ADC Therapeutics SA (NYSE:ADCT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,430 shares of the company’s stock, valued at approximately $35,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in ADC Therapeutics by 164.
1% in the third quarter. JPMorgan Chase & Co. now owns 78,813 shares of the company’s stock worth $248,000 after buying an additional 48,976 shares during the period.
Platinum Investment Management Ltd. raised its position in shares of ADC Therapeutics by 11.6% in the 4th quarter.
Platinum Investment Management Ltd. now owns 1,612,556 shares of the company’s stock worth $3,209,000 after acquiring an additional 168,040 shares in the last quarter. Charles Schwab Investment Management Inc.
lifted its stake in shares of ADC Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc.
now owns 194,258 shares of the company’s stock valued at $612,000 after purchasing an additional 18,796 shares during the period. Geode Capital Management LLC boosted its position in shares of ADC Therapeutics by 15.6% during the third quarter.
Geode Capital Management LLC now owns 953,171 shares of the company’s stock valued at $3,002,000 after purchasing an additional 128,454 shares in the last quarter. Finally, Barclays PLC grew its stake in ADC Therapeutics by 277.4% in the third quarter.
Barclays PLC now owns 127,739 shares of the company’s stock worth $402,000 after purchasing an additional 93,890 shares during the period. Hedge funds and other institutional investors own 41.10% of the company’s stock.
ADC Therapeutics Price PerformanceShares of ADC Therapeutics stock opened at $1.22 on Friday. The stock has a market cap of $120.
39 million, a price-to-earnings ratio of -0.51 and a beta of 1.55.
ADC Therapeutics SA has a 1 year low of $1.05 and a 1 year high of $5.17.
The firm’s 50-day moving average is $1.55 and its 200 day moving average is $2.11.
ADC Therapeutics (NYSE:ADCT – Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
35) by $0.06. The firm had revenue of $19.
00 million during the quarter, compared to the consensus estimate of $19.01 million. On average, equities analysts expect that ADC Therapeutics SA will post -1.
69 EPS for the current fiscal year. Wall Street Analysts Forecast GrowthADCT has been the subject of several recent research reports. Guggenheim lowered their price objective on ADC Therapeutics from $10.
00 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th.
Stephens upped their price objective on shares of ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, February 24th.
Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of ADC Therapeutics in a report on Monday, March 31st. Five analysts have rated the stock with a buy rating, According to MarketBeat.
com, ADC Therapeutics has a consensus rating of “Buy” and an average price target of $7.75.Check Out Our Latest Stock Analysis on ADC TherapeuticsAbout ADC Therapeutics (Free Report)ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.Featured StoriesFive stocks we like better than ADC TherapeuticsWhat is an Earnings Surprise? JPMorgan is a Buy, if You Can Handle The Volatility About the Markup CalculatorUnited States Steel’s Crash: An Unmissable Buying OpportunityHow to buy stock: A step-by-step guide for beginners Rocket Lab Stock: Weathering the Storm, Time for a Comeback?.
